share_log

Novartis Announces Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In HR+/HER2- Early Breast Cancer

Novartis Announces Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In HR+/HER2- Early Breast Cancer

諾華宣佈Kisqali獲CHMP積極意見,有助於降低HR+/HER2-早期乳腺癌復發風險
Benzinga ·  10/18 06:50

Novartis Announces Positive CHMP Opinion For Kisqali To Help Reduce Risk Of Recurrence In HR+/HER2- Early Breast Cancer

諾華宣佈Kisqali獲CHMP積極意見,有助於降低HR+/HER2-早期乳腺癌復發風險

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論